Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

- RDEA806 safe and well tolerated in single-dose and multiple-dose studies

up to 14 days - No evidence of CNS disturbances, rash or elevations in lipids, side

effects observed with other NNRTIs - Pharmacokinetics support further investigation with once- and twice-daily

dosing - Preclinical and Phase 1 clinical data indicate a low propensity for

drug-drug interactions

CHICAGO, Sept. 19 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC) today presented the results of Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Posters A-1429 and A-1430, Poster Session 160, Antiviral Agents]. To view the posters on-line, go to http://www.ardeabio.com.

Two double-blind, placebo-controlled, Phase 1 studies, conducted in 92 healthy adult male volunteers, of which 78 received RDEA806, demonstrated that RDEA806 was safe and well-tolerated at all doses evaluated with no serious adverse events or clinically significant laboratory or ECG abnormalities. After dosing for up to 14 days at up to 1,000 mg per day, there was no evidence of CNS disturbances or rash, side effects that have been observed with other NNRTIs that are currently marketed or in development. Furthermore, plasma cholesterol and triglyceride levels, which have been shown to increase with many HIV drugs, were stable or decreased during RDEA806 dosing.

The systemic exposure of RDEA806 increased linearly from 50 mg to 600 mg under fasted or fed conditions. The terminal half-life of RDEA806 was up to 11 hours after single doses and up to 13 hours following multiple doses. With doses of 300 mg to 500
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... 4, 2015 P&S Market ... overview, trends, DRO analysis, market segmentation, market size ... and top competitor profiles in: Global ... Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC on Global ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
(Date:8/4/2015)... Louis, Missouri (PRWEB) , ... August 04, 2015 ... ... Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership team ... track record of sales success at technology companies and expanding global markets with ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic Health System ... its kind in New Jersey, which starting this Fall will help prepare those entering ... partnered with Atlantic Health System, one of the largest health care organizations in New ...
(Date:8/4/2015)... York (PRWEB) , ... August 04, 2015 , ... It’s ... begin to describe the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI ... learn how to look better. , Naimie’s Beauty Center has been a favorite of ...
(Date:8/4/2015)... , ... August 04, 2015 ... ... HealthCenter personal health record (PHR) product has achieved Office of the National ... EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal health ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3
... women in the Nurses' Health Study has shown that Type ... the most common form of glaucoma//, accounting for about 60 ... the July issue of the journal Ophthalmology. ,Researchers ... ,Hospital, Harvard School of Public Health and Harvard Medical School ...
... used to reduce the levels of LDL cholesterol in ... cause serious muscle// damage. ,Health Canada has ... Pravachol, Zocor, Crestor and Mevacor to include warnings and ... safety information sheets. ,Statin drug users usually ...
... including MRSA, has found its way to the markets of ... one of the few new antibiotics to come on to ... organisms have undergone mutations that enabled them to develop resistance ... MRSA, in hospitals. ,The new drug Tygacil is ...
... degeneration (AMD) is twice as common in elderly smokers as ... the elderly who ate fish at least twice weekly are ... eat fish less than once a week. ... who work at the Massachusetts Eye and Ear Infirmary, which ...
... significantly reduce the load of HIV in Africa.// ... Journal PLoS Medicine, was done on a research, published ... in heterosexual men by about 60%. Now an international ... the research, across Africa to predict the potential impact. ...
... detailing the rampant sexual abuse in NHS mental units is ... in UK eight months ago. //The report says that more ... in the last 24 months. ,The Times newspaper ... which three resulted in pregnancy. Health officials maintain that the ...
Cached Medicine News:Health News:Type 2 Diabetes Increases the Risk of Glaucoma in Women 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Save your Vision with Fish Oil and Quitting Smoking 2Health News:Practise Of Male Circumcision In Africa May Reduce HIV Risks 2
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: